DEA Reports Sharp U.S. Resurgence Of Ultra-Potent Opioid Carfentanil
The Drug Enforcement Administration reports a sharp U.S. resurgence of the ultra-potent opioid carfentanil. The agency's recent bulletin warns dealers are substituting it for fentanyl to increase street potency, raising overdose risks. The trend was highlighted in recent national reporting that flagged a growing presence of the drug in multiple regions.
Carfentanil is being described in coverage as "weapons-grade" and highly lethal at very small doses, which complicates harm-reduction and emergency responses. Health officials say this trend could worsen the overdose crisis and make frontline interventions more dangerous and unpredictable.
Earlier mainstream reporting focused largely on fentanyl as the primary driver of rising overdose deaths. Recent bulletins and stories, including ABC News' coverage, have shifted attention toward carfentanil's return and the distinct risks it poses, prompting renewed calls for expanded prevention, testing, and treatment efforts.
📌 Key Facts
- DEA labs found carfentanil in 1,400 U.S. drug seizures in 2025, compared with 145 in 2023 and 54 in 2022.
- Carfentanil is estimated to be 10,000 times more potent than morphine and 100 times stronger than fentanyl; a poppy seed–sized amount can be lethal.
- Customs and Border Protection reports fentanyl seizures fell to about 12,000 pounds in 2025, less than half the 2023 total.
- Experts warn even multiple high doses of naloxone may not reverse carfentanil overdoses, heightening risk for unsuspecting users.
- DEA intelligence links the carfentanil spike to Chinese precursor crackdowns and Mexican traffickers boosting weaker fentanyl with carfentanil.
📰 Source Timeline (1)
Follow how coverage of this story developed over time